Literature DB >> 24798478

Single compartment drug delivery.

Michael J Cima1, Heejin Lee2, Karen Daniel2, Laura M Tanenbaum3, Aikaterini Mantzavinou3, Kevin C Spencer4, Qunya Ong3, Jay C Sy5, John Santini6, Carl M Schoellhammer7, Daniel Blankschtein7, Robert S Langer5.   

Abstract

Drug design is built on the concept that key molecular targets of disease are isolated in the diseased tissue. Systemic drug administration would be sufficient for targeting in such a case. It is, however, common for enzymes or receptors that are integral to disease to be structurally similar or identical to those that play important biological roles in normal tissues of the body. Additionally, systemic administration may not lead to local drug concentrations high enough to yield disease modification because of rapid systemic metabolism or lack of sufficient partitioning into the diseased tissue compartment. This review focuses on drug delivery methods that physically target drugs to individual compartments of the body. Compartments such as the bladder, peritoneum, brain, eye and skin are often sites of disease and can sometimes be viewed as "privileged," since they intrinsically hinder partitioning of systemically administered agents. These compartments have become the focus of a wide array of procedures and devices for direct administration of drugs. We discuss the rationale behind single compartment drug delivery for each of these compartments, and give an overview of examples at different development stages, from the lab bench to phase III clinical trials to clinical practice. We approach single compartment drug delivery from both a translational and a technological perspective.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Controlled release drug delivery; Local therapy; Microfabrication; Noninvasive; Single compartment; Targeted therapy

Mesh:

Substances:

Year:  2014        PMID: 24798478      PMCID: PMC4179298          DOI: 10.1016/j.jconrel.2014.04.049

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  193 in total

Review 1.  The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery.

Authors:  D R Groothuis
Journal:  Neuro Oncol       Date:  2000-01       Impact factor: 12.300

2.  Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings.

Authors:  A L Brody; S Saxena; P Stoessel; L A Gillies; L A Fairbanks; S Alborzian; M E Phelps; S C Huang; H M Wu; M L Ho; M K Ho; S C Au; K Maidment; L R Baxter
Journal:  Arch Gen Psychiatry       Date:  2001-07

Review 3.  The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis.

Authors:  Christopher Chapple; Vik Khullar; Zahava Gabriel; Julie Ann Dooley
Journal:  Eur Urol       Date:  2005-03-22       Impact factor: 20.096

4.  Mesenchymal stem cell-conditioned medium accelerates skin wound healing: an in vitro study of fibroblast and keratinocyte scratch assays.

Authors:  M N M Walter; K T Wright; H R Fuller; S MacNeil; W E B Johnson
Journal:  Exp Cell Res       Date:  2010-03-03       Impact factor: 3.905

Review 5.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

6.  Direct, quantitative, and noninvasive imaging of the transport of active agents through intact brain with positron emission tomography.

Authors:  Rachael W Sirianni; Ming-Qiang Zheng; W Mark Saltzman; Yiyun Huang; Richard E Carson
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

Review 7.  New frontiers in intravesical therapies and drug delivery.

Authors:  Antonella Giannantoni; Savino M Di Stasi; Michael B Chancellor; Elisabetta Costantini; Massimo Porena
Journal:  Eur Urol       Date:  2006-08-30       Impact factor: 20.096

8.  Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.

Authors:  Sarah Minner; Birte Jessen; Lars Stiedenroth; Eike Burandt; Jens Köllermann; Martina Mirlacher; Andreas Erbersdobler; Christian Eichelberg; Margit Fisch; Tim Henrik Brümmendorf; Carsten Bokemeyer; Ronald Simon; Thomas Steuber; Markus Graefen; Hartwig Huland; Guido Sauter; Thorsten Schlomm
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

Review 9.  Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity.

Authors:  Karin Glavind; Michael Chancellor
Journal:  Int Urogynecol J       Date:  2011-04-06       Impact factor: 2.894

10.  Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland.

Authors:  Carl P Nelson; Paul Gupta; Carolyn M Napier; Stefan R Nahorski; R A John Challiss
Journal:  J Pharmacol Exp Ther       Date:  2004-05-12       Impact factor: 4.030

View more
  6 in total

Review 1.  Advances in Biomaterials for Drug Delivery.

Authors:  Owen S Fenton; Katy N Olafson; Padmini S Pillai; Michael J Mitchell; Robert Langer
Journal:  Adv Mater       Date:  2018-05-07       Impact factor: 30.849

Review 2.  Principles of pharmacology in the eye.

Authors:  Sahar Awwad; Abeer H A Mohamed Ahmed; Garima Sharma; Jacob S Heng; Peng T Khaw; Steve Brocchini; Alastair Lockwood
Journal:  Br J Pharmacol       Date:  2017-10-10       Impact factor: 8.739

Review 3.  Low-dose versus standard-dose bacille Calmette-Guérin for non-muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized controlled trials.

Authors:  Se Young Choi; Moon Soo Ha; Jung Hoon Kim; Byung Hoon Chi; Jin Wook Kim; In Ho Chang; Tae-Hyoung Kim; Soon Chul Myung
Journal:  Investig Clin Urol       Date:  2022-03

Review 4.  Novel targeted bladder drug-delivery systems: a review.

Authors:  Martino Maria Zacchè; Sushma Srikrishna; Linda Cardozo
Journal:  Res Rep Urol       Date:  2015-11-23

Review 5.  The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer.

Authors:  Laura Douglass; Mark Schoenberg
Journal:  Bladder Cancer       Date:  2016-07-27

6.  Optimal Magnetic Field for Crossing Super-Para-Magnetic Nanoparticles through the Brain Blood Barrier: A Computational Approach.

Authors:  Maysam Z Pedram; Amir Shamloo; Aria Alasty; Ebrahim Ghafar-Zadeh
Journal:  Biosensors (Basel)       Date:  2016-06-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.